Identification of genes involved in growth inhibition

Introduction
Breast cancer is one of the leading causes of premature death in women in occidental countries [1] . Increased lifetime exposure to estrogens is an established risk factor for development of breast cancer. Estrogen action is mediated by two estrogen receptors ERα and ERβ. ERβ is poorly expressed in breast tumors [2] . A high percentage of early stage mammary tumors are estrogen receptor α (ERα)-positive and about 50% of these patients respond to anti-estrogen or endocrine therapy [3, 4] . Later stages of breast cancer are more aggressive and refractory to most therapies and this correlates with the ERα-negative phenotype of these tumors [5] . ERα-positive tumor cells are poorly metastatic in nude mice when compared with some ERα-negative breast cancer cells [6] . In patients, ERα-positive tumors are more differentiated and have lower metastatic potential than ERα-negative tumors [7] , suggesting a protective role of the ERα in tumor progression. Introduction of ERα into ER-negative breast cancer cells has been thought to provide a rational basis for converting anti-estrogen resistant cells to hormonal manipulation.
However, in contrast to the expected stimulated proliferation of ER-positive cells, the restoration of ERα expression in ER-negative breast cancer cells leads to a ligand-dependent inhibition of proliferation as shown by numerous studies [8] [9] [10] [11] . The mechanisms underlying this phenomenon have been poorly investigated and could be of great interest to control the proliferation of these aggressive types of tumor cells. The goal of this study was to discerne events responsible for the ligand-dependent inhibition of breast cancer cells expressing exogenously ERα by analysing possible cell cycle regulation and modulation of gene expression.
Materials and Methods
Recombinant adenovirus construction and propagation.
The complete coding sequence of wild-type hERα cDNA was subcloned in BamHI site of the pACsk12CMV5 shuttle vector. To obtain recombinant viruses, permissive HEK-293 cells (human embryonic kidney cells) were cotransfected with the backbone or recombinant pACsk12CMV5-hER plasmid and with pJM17, which contains the remainder of the adenoviral genome as previously described [11] . In vivo recombination of the plasmids generates HAL author manuscript inserm-00143969, version 1 infectious viral particles Ad5 (backbone virus) and Ad-hERα). Titered virus stocks were used to infect MDA-MB-231 cells.
Cell Culture and infection
MDA-MB-231 cells were maintained in Leibowitz L-15 medium supplemented with 10% fetal calf serum (FCS) and gentamycin. To wean the cells off steroids, they were cultured in phenol red-free DMEM/F12 supplemented with 10% CDFCS (charcoal dextran-treated FCS) for 4 days.
For infection, cells were cultured in the same medium and infected with Ad5 or Ad-hERα viruses at a multiplicity of infection (MOI) of 100.
Whole cell extract preparation and western blot.
Cell extracts were prepared in NP40 buffer [50mM Tris-HCl pH 8.0, 150mM NaCl, 1% NP40, 
Flow Cytometry Experiments.
To analyze the effects of recombinant viruses on the cell cycle, MCF-7 cells were infected with the adenoviral vectors, and cells were fixed in Ethanol 75% for 2 min. Fixed cells were then stained with PBS containing 40µg/ml propidium iodide and 100 µg/ml RNAse. After a 30 min incubation at 37°C, analysis was performed on an Epics-XL flow cytometer (Beckman Coulter, Fullerton, CA).
RNA extraction, Northern blot and cDNA Microarrays.
Total RNA was isolated with TRIzol reagent (Invitrogen) as described by the manufacturer.
RNA quantity was checked photometrically by absorption at 260 nm and quality was determined by examination of the 28S and 18S rRNA bands in ethidium bromide-stained agarose gels. After 
Results
Growth inhibition involves G2/M transition blockage
We have previously showed that exogenous expression of ERα in MDA-MB-231 ER-negative breast cancer leads to growth inhibition in the presence of estradiol [11] . To better characterize HAL author manuscript inserm-00143969, version 1 the phenomenon involved in growth inhibition, we performed flow cytometry experiments on cells which had been treated for different times with estradiol ( Fig. 1) . Cell cycle distribution of Ad5 infected remained unchanged upon estrogen treatment. On the other hand, Ad-hERα infected cells cell cycle distribution was strongly affected. The proportion of ERα cells in S phase strongly diminished upon treatment with estradiol (27 to 16%), whereas the proportion of cells in G1 phase was constant and the proportion of cells in G2/M phase increased from 13 to 17%. Importantly, we should also notice the presence of a sub-G1 peak which is characteristic of cells undergoing apoptosis (Fig. 1 ).
Analysis of cell cycle modulators expression
To dissect the mechanisms underlying this inhibition of proliferation, we analyzed at the protein level the expression of a collection of known cell cycle modulators. A time course of estradiol treatment was performed on Ad5 or Ad-hERα infected cells and whole cell extracts were analyzed by western blot (Fig. 2) . ERα was only detected in Ad-hERα infected cells. Of particular note is the appearance of a slower migrating band upon estradiol treatment which could correspond to a phosphorylated form of ERα. ERK phosphorylation did not show any modification whereas pRb phosphorylation was strongly diminished. Cyclins D1 and E were upregulated in a ligand-independent manner, whereas cyclin A and D3 expression remained constant. CDKI p21 and p27 showed a nice up-regulation following estradiol treatment. Finally, cdc2 and cdk2 levels were stable. In summary, these data show a complex regulation of cyclins and CDKI involved in G1 to S phase transition.
Liganded-ERα α induces a complex pattern of gene regulation
To have a better sense of the mechanisms underlying the growth inhibitory effect of liganded-ERα, we compared the expression of 588 genes between ERα-infected cells treated or not with E2, by using cDNA macroarrays. A total of 12 genes were up-regulated by E2 (Table 1) , whereas 27 genes were down-regulated by E2 ( Table 2 ). The genes identified were potentially involved in oncogenesis or tumor suppression (RAF, c-myc, c-fms, c-jun, Fra-1, Axl), cell cycle 
Confirmation of the regulations by northern blot
To confirm the regulations identified by cDNA array screening, we analyzed the expression of 13 genes by northern blot (Fig. 3 ). pS2 gene (not present on the array) was used as a positive control of estrogen regulation and it was induced only in Ad-ERα infected cells treated with E2.
We observed that the levels of Fra-1, Gadd45, DAP-3 and TopoIIα and DNA-PK were effectively down-regulated by liganded-ERα, whereas cyclin G2, G-CSF, IL1β, Macmarcks, BNIP3, p21/CIP-1 and TGFα levels were up-regulated, which validates our screen.
Discussion
To identify the mechanisms underlying cell growth inhibition triggered by liganded-ERα in ERnegative breast cancer cells, we have analyzed cell cycle distribution and gene expression changes. Our results suggest that cycle cycle blockage in G2/M phase occurs, which is concomittant with an up-regulation of p21, p27, TOB and cyclin G2 levels, a down-regulation of STK1 expression and a dephosphorylation of pRb. p21, p27, TOB and cyclin G2 have been shown to inhibit proliferation [13] [14] [15] , whereas STK1 overexpression could increase proliferation [16] . The down regulation of Gadd45 which expression is frequently increased in growtharrested cells and regulated by BRCA-1 [17] might be explained by the down-regulation of BRCA-1 we observed previously in such infected cells [18] . On the other hand, apoptosis is also likely to occur as shown by appearance of a subG1 peak, induction of pro-apoptotic BNIP3 [19] HAL author manuscript inserm-00143969, version 1
and down-regulation of DAP-3 [20] . It is also interesting to note that several oncogenes such as c-myc, c-fms, c-jun, Fra-1, Axl, or transcription factors such as ATF-2, ATF4, HIP116, CNBP or Y box are down regulated. All these proteins are generally promoting tumorigenesis [21] [22] [23] [24] [25] [26] .
Abnormal expression of c-fms, Axl, members of AP-1 family, CNBP (which stimulates c-myc promoter activity) or Y-box protein by malignant cells is correlated with poor prognosis [21] [22] [23] [24] [25] 27] . Down regulation of Topoisomerase IIα, HHR23A, HHR23B, DBI/ACBP and to a lesser extent of DNA-PK suggests that reintroduction of ERα in MDA-MB-231 cells leads to a decreased efficiency of DNA repair [28] [29] [30] , which could eventually lead to apoptosis. In addition to the weaker ability of the cells, to defend themselves against DNA damage, it is likely that the cells are also losing their ability to respond to stress signals as shown by downregulation of HSP60, glutathione peroxidase and glutathione reductase [31, 32] . Changes in integrin and BMP-4 [33, 34] could also account for the previously observed inhibition of invasion observed after reintroduction of ERα [9] . Other events such as down regulation of thrombin receptor, up-regulation of thrombomodulin could also account for the decreased invasiveness of these cells [35] [36] [37] . In addition, the down regulation of CTGF, which is promoting angiogenesis [38] , suggests that ERα exogenous expression could reduce the angiogenesis events during tumor formation. It is also interesting to note that, the majority of the genes regulated by E2 that we discovered, have not been previously identified as potential targets of ER, confirming the importance of our screen.
In conclusion, our data suggest that reintroduction of ERα in ER-negative breast cancer cells could be a valuable strategy to limit their growth and their invasion. This is also concomitant to a reduced ability to repair damaged DNA and to response to stress signals, which further suggests that the cells are more likely to lose their advantages over normal cells. 
